Azierta Blog

This week we are present in FOOD 4 FUTURE – EXPO FOODTECH 2022, with the aim of strengthening synergies and collaborations with the #agrofood sector. Ignacio Vieira, Care, Audits & Certifications, Health & Infrastructures, and DS&G Director & Jose Luis Prieto de la Hormaza, Key Account Manager have attended with the mission and value of continuing to explore opportunities […]

ICH Q3D   The first version of the ICH Q3D guidance was published in 2016, to control elemental impurities in medicinal products for human use within acceptable limits. For veterinary medicinal products, it was recently published in early 2020. The presence of elemental impurities in pharmaceuticals has traditionally been monitored by the so-called heavy metal […]

Azierta has been present at Vitafoods Europe 2022, the most important event in the nutraceutical sector attended by experts from the health and nutrition industry from more than 100 countries. Vitafoods Europe is one of the most important business oriented nutrition fairs. During these days, the most important suppliers of ingredients and technology for dietary supplements […]

This month we interview Ignacio Vieira, Audit & Certification, Healthcare, DSG & AZ Health Consortium Director at Azierta who talks to us about AZIERTA CARE and the importance of diversifying markets.  A talk in which our expert discusses the birth of the new unit, Azierta Care, its main services and its launch as an international boutique consultancy […]

Impurities are defined in ICH Q6A guideline as “Any component of the drug product that is not the chemical entity defined as the drug substance or an excipient in the drug product. The impurities in drug products can be originated not only in the drug substance or inert ingredients used for formulating a drug product; […]

On February 2020 the EU published that titanium dioxide must be classified as carcinogen if inhaled (Carc. 2, H351 (inhalation) in certain powdered forms under the CLP Regulation. Moreover, on May 2021 the European Food Safety Authority (EFSA) published an updated safety assessment of the food additive titanium dioxide (E 171) concluding that titanium dioxide can […]

This week we received a visit from Ángel Fernández, Global Senior Executive, Pharmaceuticals, Business Advisor, Health Care, MSD SVP Europe, US, Latam. Ángel met with the President of Azierta, Ángel Navarro, and part of the management team to learn first-hand about the work that our company carries out in the different business units. The experience […]

This week was held DIA Europe 2022, an event that brings together the knowledge between science and regulation of the Life Sciences industry. In this edition Azierta participated with a Live Content Hub on Strategic Safety and Pharmacovigilance led by Eduardo Ródenas, Senior Drug Safety Officer. A dynamic talk in which the main challenges in […]

On 28/01/2022, the new Regulation (EU) 2019/6 on veterinary medicinal products and Commission Implementing Regulation (EU) 2021/1281, laying down rules for application as regards good pharmacovigilance practice and on the format, content and summary of the pharmacovigilance system master file for veterinary medicinal products entered into force. As a result, Directive 2001/82/EC and Regulation (EC) […]

The Catholic University of Murcia (UCAM) and Azierta, a consultancy firm that specialises in life and health sciences, have signed a collaboration agreement through which they are introducing the ‘Life Sciences’ department. Their main objective is to build a relationship between the university and the pharmaceutical and health industry, as such, one of their first […]